Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of
fundamentally different diseases with different histologic, genomic, and immunologic …

Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Background Preferred neoadjuvant regimens for early-stage triple-negative breast cancer
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …

PARP inhibitors (PARPi) have drastically changed the treatment landscape of advanced
ovarian tumors with BRCA mutations. However, the impact of this class of inhibitors in …

Background Understanding the impact of the tumor immune microenvironment and
BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint …

Simple Summary For decades, countless efforts have been devoted to develo** targeted
drugs to improve the prognosis of triple-negative breast cancer (TNBC). Among the novel …

For decades, the systemic treatment of localized triple negative breast cancer (TNBC) has
exclusively relied on chemotherapy. Recent advancements, however, are rapidly resha** …

Breast cancer is the most commonly occurring cancer in women. There were over two-
million new cases in world in 2018. It is the second leading cause of death from cancer in …

Recent progress in immunobiology has led the way to successful host immunity
enhancement against breast cancer. In triple-negative breast cancer, the combination of …

Opinion statement In approximately 15–20% of the patients diagnosed with breast cancer, it
comprises the triple negative (TN) subtype, which until recently lacked targets for specific …